- Zenas BioPharma Inc.
Zenas BioPharma Inc.
Website
Offer Price
Offer Size
3-Year Outlook
Volatility
1st Day Turnover
$17.00
13,200,000
Positive
High
14.58%
Offering Team
Deal Managers
- Morgan Stanley
- Jefferies
- Citigroup
Lawyers
- Cooley LLP
Auditors
- Ernst & Young LLP
Pre-IPO Investors
Investors
- Google Ventures
- Intel Ventures
- Patricoff Ventures
- Kleiner Perkins
Pre-IPO Holdings(%)
- 30
- 20
- 05
- 18
Deal Highlights
We are a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. With the evolving understanding of the pathogenesis of autoimmune diseases, along with the expansion of promising immunology-based pharmacologic targets, we are building an I&I focused biopharmaceutical company. Our core business strategy combines disciplined product candidate acqui More
Deal Tracker
Investors
Filing
22 Aug, 2024Offer
13 Sep, 2024Look Ahead
Lock Up Expiry
13 Mar, 2025Earning
Nov 1, 2018IPO Terms
| Offer Price | $17.00 |
| Offer Size | 13M |